- Conditions
- Diabetic Retinopathy, Macular Edema
- Interventions
- MK-8748, Aflibercept
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 29
- States / cities
- Gilbert, Arizona • Glendale, California • Sacramento, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 434
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- pegaptanib sodium (Macugen)
- Drug
- Lead sponsor
- Palmetto Retina Center, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia
- Interventions
- Retinal fundus photography
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Diabetes, Kidney Disease, Vascular Disease, Retinopathy
- Interventions
- Montelukast, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- Dorzolamide-timolol, Artificial tears
- Drug · Other
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
- Conditions
- Wet Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
- Conditions
- Coronary Artery Disease
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- General University Hospital, Prague
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Maywood, Illinois • Iowa City, Iowa
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
- Conditions
- Retinal Vein Occlusion, Macular Edema
- Interventions
- dexamethasone intravitreal implant 0.7 mg
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Varying needle size with intravitreal ranibizumab or aflibercept
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Retinal Hemangioblastoma, Von Hippel-Lindau Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 7 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Retinopathy, Neurotrophic Keratitis
- Interventions
- Not listed
- Lead sponsor
- Medical Center Ophthalmology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
- Interventions
- Visual acuity (presenting and pinhole), Optical coherence tomography (OCT), Intraocular pressure, Active linkage to care, Fundus Photography
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 60,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
- Interventions
- ranibizumab 0.5mg, ranibizumab 1.0mg
- Drug
- Lead sponsor
- Hanscom, Thomas, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
- Conditions
- Diabetic Retinopathy, Macular Degeneration
- Interventions
- intravitreal injection of infliximab
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
- Interventions
- Retinal and Choroidal Imaging
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Retinopathy of Prematurity
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- Vision Research Foundation
- Other
- Eligibility
- 30 Weeks to 36 Weeks
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- FYB203 2 mg (0.05 mL of 40 mg/mL)
- Drug
- Lead sponsor
- Formycon AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Campbell, California • Long Beach, California • Redlands, California + 1 more
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy
- Interventions
- EyePromise DVS, EyePromise DVS plus EyePromise EZTears
- Dietary Supplement
- Lead sponsor
- ZeaVision, LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Dorzolamide-timolol
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Physician-guided diagnostic
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- ADVM-022
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Reno, Nevada • Philadelphia, Pennsylvania + 3 more
- Conditions
- Diabetic Retinopathy (DR)
- Interventions
- Fundus Image Grading
- Diagnostic Test
- Lead sponsor
- Artelus AI
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Oxford, North Carolina • Raleigh, North Carolina
- Conditions
- Diabetes Complications, Diabetic Retinopathy
- Interventions
- Generation of inducible pluripotent stem cells
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years to 98 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama